我最初想知道是否 $諾瓦瓦克斯醫藥(NVAX.US$ 無法開發 KP COVID 菌株疫苗,並堅持 JN 將是一件壞事,但反思後,JN 系列似乎仍然主導,所以仍然存在許多優勢(FDA 現在希望秋季 COVID 疫苗瞄準 KP.2-但並非所有製造商都可以轉向)
已翻譯
![圖片](https://sgsnsimg.moomoo.com/sns_client_feed/102286586/20240718/ac234f5f4d62906203dbba361b8f4655.jpg?area=101&is_public=true)
1
已翻譯
1
$波音(BA.US$ 嗯,尖刺怎麼了?
已翻譯
3
2
今天有趣的發布分享更多關於 $美特爾(5DX.SG$在照護提供方面的數字化雄心。價格回到他們轉變之前的位置,看到願景發展很高興 https://links.sgx.com/1.0.0/corporate-announcements/17QGG3JJHUHV6XRY/
已翻譯
1
$Zogenix(ZGNX.US$ acquisition - up 65% overnight, buy and sell high
1
So in the pharma world today…
$聯合利華(英國)(UL.US$ said they won’t bid for $葛蘭素史克(GSK.US$ - share price impact on both? I’d have said lower for Unilever because the acquisition would be good for their fundamentals and the market knows it, GSK down because they miss out on billions. Let’s see
$賽諾菲安萬特(SNY.US$ and $再生元製藥公司(REGN.US$’s Duxipent PRIME 2 study in atopic dermatitis has good data - I guess price goes up
$Zogenix(ZGNX.US$ to be bought by UCB...
$聯合利華(英國)(UL.US$ said they won’t bid for $葛蘭素史克(GSK.US$ - share price impact on both? I’d have said lower for Unilever because the acquisition would be good for their fundamentals and the market knows it, GSK down because they miss out on billions. Let’s see
$賽諾菲安萬特(SNY.US$ and $再生元製藥公司(REGN.US$’s Duxipent PRIME 2 study in atopic dermatitis has good data - I guess price goes up
$Zogenix(ZGNX.US$ to be bought by UCB...
有沒有其他人想以這種方式投資?看看那天有什麼好消息可能會推動市場,投資於一堆公司,將其視為投資組合。今天嘗試這個 $藥品製造商 - 一般(LIST2428.US$股票:
$輝瑞(PFE.US$普拉克索維德對奧米克龍的結果可能會推動它升高
$EQRx(EQRX.US$達到三期末端點的蘇格瑪巴利布
$阿斯利康(AZN.US$喜馬拉雅研究的詳細信息顯示 22% 的 OS 對肝癌有益
$UCB S.A. UNSP ADR EACH REPR 0.5 ORD(UCBJY.US$比姆澤爾克斯達成...
$輝瑞(PFE.US$普拉克索維德對奧米克龍的結果可能會推動它升高
$EQRx(EQRX.US$達到三期末端點的蘇格瑪巴利布
$阿斯利康(AZN.US$喜馬拉雅研究的詳細信息顯示 22% 的 OS 對肝癌有益
$UCB S.A. UNSP ADR EACH REPR 0.5 ORD(UCBJY.US$比姆澤爾克斯達成...
已翻譯
1
4
已翻譯
2